17 completed, 9 recruiting, 4 active not recruiting, 4 withdrawn. 24 Phase 2, 8 Phase 4, 7 Phase 3, 5 Phase 1, 3 Not applicable.
Follow testosterone 17 beta-cypionate: new trials by email Literature Review of testosterone 17 beta-cypionate trials Research Report on testosterone 17 beta-cypionate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance Testosterone cypionate - Prostate Cancer, Hypogonadism, Male | Phase 4 | Recruiting | University of Miami | 35 | 2026-11-30 | 2026-11-02 |
| Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism Testosterone Cypionate 75 mg, Testosterone cypionate 50 mg, Testosterone cypionate 100 mg - Male Hypogonadism | Phase 3 | Recruiting | Amneal Pharmaceuticals, LLC | 190 | 2026-09-28 | 2026-10-27 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617 - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2026-03-03 | 2026-05-15 |
| Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men Testosterone Cypionate Injection 200 mg/mL - Hypogonadism, Male | Phase 4 | Not yet recruiting | Azurity Pharmaceuticals | 144 | 2026-02-01 | 2026-01-09 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-10-30 |
| Androgen Effects on the Reproductive Neuroendocrine Axis Testosterone Cypionate 50 MG/ML Injectable Solution - Transgenderism, Reproductive Issues | Phase 4 | Terminated | University of California, San Diego | 2 | 2025-02-26 | 2025-07-22 |
| The Anabolic Effect of Testosterone on Pelvic Floor Muscles Testosterone cypionate, Placebo - Stress Urinary Incontinence, Menopause | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 30 | 2025-02-15 | 2026-06-26 |
| Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Biopsy, Bone Scan, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 3 | 2024-12-19 | 2026-08-07 |
| TESTO-TRIAL: Use of Testosterone in Critically Ill Patients Testosterone cypionate (200mg/3ml), Sesame oil (3ml) - Weaning Failure, Muscle Weakness | Phase 4 | Active not recruiting | Leticia Maria Defendi Barboza Marson | 94 | 2024-09-09 | 2024-12-18 |
| Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 69 | 2024-05-21 | 2026-07-21 |
| Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC Testosterone Cypionate, Sipuleucel-T - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Yale University | 26 | 2023-12-20 | 2026-09-10 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2023-10-04 | 2026-01-14 |
| Hormone Secretion in Transgender Males Testosterone Cyp 200Mg/Ml Inj (in Oil), Letrozole - Transgender, Healthy | Phase 4 | Withdrawn | University of California, San Diego | 2023-07-01 | 2025-01-13 | |
| Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial) Testosterone Cypionate, Placebo - Pain, Opioid Use | Phase 2 | Completed | Brigham and Women's Hospital | 36 | 2022-11-15 | 2026-04-15 |
| Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis Testosterone Cypionate 100 MG/ML - Testosterone, Transsexualism | Not applicable | Completed | University of Sao Paulo | 46 | 2022-09-01 | 2025-03-28 |
| Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair Testosterone cypionate, Placebos - Rotator Cuff Tears | Phase 2 / Phase 3 | Withdrawn | Orthopedic Institute, Sioux Falls, SD | 2021-08-01 | 2022-03-15 |
Showing 20 of 42. Sign in to see all of them.
Prostatic Neoplasms (15) · Eunuchism (5) · Hypogonadism (5) · Transsexualism (3) · Gender Dysphoria (2) · Anorexia Nervosa (1) · Back Pain (1) · Bone Diseases (1) · Bone Resorption (1) · Central Nervous System Diseases (1) · Critical Illness (1) · Endocrine System Diseases (1) · Fatigue (1) · Genital Diseases (1) · Genital Diseases, Male (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (10) · Brigham and Women's Hospital (2) · University of California, San Diego (2) · University of Miami (2) · University of Washington (2) · VA Office of Research and Development (2) · Amneal Pharmaceuticals, LLC (1) · Azurity Pharmaceuticals (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Enhanced Emirates Limited (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hospital Sirio-Libanes (1) · Hospital de Clinicas de Porto Alegre (1)
United States (33) · Brazil (5) · Canada (1) · United Arab Emirates (1)
Samuel Denmeade, MD (8) · Michael Schweizer (2) · Sandeep Dhindsa, MD (2) · Abraham Morgentaler, MD (1) · Alberto J Pacheco, BA (1) · Antoni Duleba, MD (1) · Bruce Kava, MD (1) · Craig W Spellman, DO (1) · Diogo Assed Bastos (1) · Grace Huang, MD (1) · Jingsong Zhang, MD, PhD (1) · Joseph W Kim, MD (1) · Joshua F Yarrow, PhD MS BS (1) · Keith M Baumgarten, MD (1) · Kenneth Ogan, MD (1)
PMID 29248236, PMID 32624280, PMID 33383350, PMID 33617303, PMID 33735389, PMID 35027313, PMID 35027909, PMID 35938545, PMID 37126399, PMID 38167882, PMID 39705803, PMID 41052128, PMID 42113507
P30CA015704 (1), P30CA138292 (1), P50CA097186 (1), P50CA272391 (1), R01AG060539 (1), R01CA184012 (1), R01DK136904 (1), R01HD111650 (1), U10CA180820 (1), UL1TR001082 (1)